Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries

What Was Tested

This clinical trial paper looks at Insulin Aspart.

The aim of this study was to investigate clinical outcomes in people with type 2 diabetes (T2D) after initiating IDegAsp treatment in a real-world setting.

Why It Was Studied

Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (a basal insulin) and insulin aspart (a prandial insulin).

Who Took Part

The abstract describes 1102 adults taking part.

PubMed indexes the participants as adults.

Data were obtained from 1102 adults with T2D initiating or switching to IDegAsp from antidiabetic treatments (including oral antidiabetic drugs, basal insulin, basal-bolus insulin, premix insulin, and glucagon-like peptide 1 receptor agonist) per local clinical practice.

How the Study Was Run

In design terms this was a open-label study.

Nothing was hidden in this open-label Insulin Aspart study: the adults and staff both knew the treatment.

This 26-week, open-label, non-interventional study was conducted in Australia, India, Malaysia, Philippines, Saudi Arabia, and South Africa.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Drug Combinations, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin.

Author keywords: Glycaemic control, Insulin degludec/insulin aspart, Real-world and Type 2 diabetes.

What This Means in Plain Language

The paper is an open-label study of Insulin Aspart in 1102 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Advances in therapy), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.